Fang Xu
- Cancer Research top 10%
- Cancer-related molecular mechanisms research 6
- Cancer Genomics and Diagnostics 5
- Molecular Biology top 10%
- RNA modifications and cancer 7
- RNA Research and Splicing 5
- Oncology top 10%
- Cancer Immunotherapy and Biomarkers 5
- Infectious Diseases top 10%
- Tuberculosis Research and Epidemiology 9
-
- Lung Cancer Treatments and Mutations 8
-
- Mycobacterium research and diagnosis 5
- Co-authors
- Parker L. AndersenWei XiaoLin SunJieqiong LiMichael H. MaloneClark DistelhorstMichael J. ThomeniusFei Zhong
- Journals
- Journal of Biological Chemistry (2 papers)Journal of Clinical Oncology (1 paper)SHILAP Revista de lepidopterología (1 paper)
- Partner nations
- ChinaUnited StatesRussia
In The Last Decade
Fang Xu
91 papers receiving 1.8k citations
Peers
Comparison fields: 5 of 135
- Cancer Research 259
- Molecular Biology 870
- Oncology 275
- Infectious Diseases 172
- Immunology 193
Countries citing papers authored by Fang Xu
This map shows the geographic impact of Fang Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fang Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fang Xu more than expected).
Fields of papers citing papers by Fang Xu
This network shows the impact of papers produced by Fang Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fang Xu. The network helps show where Fang Xu may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Fang Xu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2025 | 0 | |
| 3 | 2024 | 14 | |
| 4 | 2024 | 0 | |
| 5 | 2024 | 0 | |
| 6 | 2023 | 7 | |
| 7 | 2022 | 4 | |
| 8 | 2021 | 2 | |
| 9 | 2019 | 3 | |
| 10 | 2018 | 56 | |
| 11 | 2018 | 20 | |
| 12 | 2017 | 18 | |
| 13 | 2017 | 86 | |
| 14 | 2015 | 2 | |
| 15 | 2015 | 0 | |
| 16 | 2013 | 3 | |
| 17 | [Study on chemical constituents of Hyssopus cuspidatus]. | 2013 | 6 |
| 18 | 2009 | 18 | |
| 19 | 2003 | 127 | |
| 20 | 1998 | 4 |
About Fang Xu
Fang Xu is a scholar working on Cancer Research, Aging and Infectious Diseases, having authored 102 papers that have together received 1.8k indexed citations. Recurring topics across this work include Tuberculosis Research and Epidemiology (9 papers), Lung Cancer Treatments and Mutations (8 papers), RNA modifications and cancer (7 papers), Cancer-related molecular mechanisms research (6 papers), Cancer Genomics and Diagnostics (5 papers), Cancer Immunotherapy and Biomarkers (5 papers), Mycobacterium research and diagnosis (5 papers) and RNA Research and Splicing (5 papers). The work is most often cited by research in Cancer Research (259 citations), Molecular Biology (870 citations) and Oncology (275 citations). Fang Xu has collaborated with scholars based in China, United States and Russia. Frequent co-authors include Parker L. Andersen, Wei Xiao, Lin Sun, Jieqiong Li, Michael H. Malone, Clark Distelhorst, Michael J. Thomenius, Fei Zhong, Weiwei Jiao and Zhengqi Wang. Their work appears in journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.